Useful links
Unit of study_
PHAR5723: Immunology and Cancer
2024 unit information
This unit of study will cover the therapeutics of immunology and cancer including the pharmaceutical sciences that underpin such drug therapies. This unit will also include the epidemiology, pathophysiology and clinical features of immunology and cancer. Through the use of case-based learning, students will participate in the interpretation, application and dissemination of pharmaceutical and pharmacotherapeutic concepts and knowledge. On completion of this unit of study students will be able to apply an understanding of the pharmaceutical sciences to optimising the drug and non-drug therapy of patients with cancer and immunological disorders. Interprofessional communication and the application of specialist knowledge to implementing pharmacist cognitive services such as clinical interventions and/or medication management review will also be explored. Students will become familiar with drug information software and a number of computerised drug information databases. Role-plays will be used to develop students' communication skills for interaction between pharmacists and their clients (patients, doctors, other health professionals).
Unit details and rules
Managing faculty or University school:
Pharmacy
| Code | PHAR5723 |
|---|---|
| Academic unit | Pharmacy |
| Credit points | 6 |
|
Prerequisites:
?
|
PHAR5911 and PHAR5712 and PHAR5713 and PHAR5714 and PHAR5715 and PHAR5716 and PHAR5717 and PHAR5718 |
|---|---|
|
Corequisites:
?
|
PHAR5721 and PHAR5722 |
| Prohibitions:
?
|
None |
| Assumed knowledge:
?
|
None |
At the completion of this unit, you should be able to:
- LO1. Demonstrate an understanding of the epidemiology and pathophysiology associated with immunological disorders and cancer
- LO2. Identify the most appropriate evidence-based treatments and the appropriate advice and counselling to patients with immunological disorders and cancer
- LO3. Demonstrate an understanding of the chemistry and pharmacology that forms the basis of structure-activity relationships, drug-drug interactions, and drug design of medicines used for immunological disorders and cancer
- LO4. Identify and manage medication-related adverse events and provide appropriate advice/counselling to patients with immunological disorders and cancer or other health care professionals
- LO5. Communicate effectively and ethically with patients, their families, and other health care professionals about the optimal management of immunological disorders and cancer
- LO6. Identify and utilise appropriate resources that are used to form the basis of decisions on which medicines and services are recommended to patients with immunological disorders and cancer and other health care professionals
- LO7. Critically examine scientific evidence, both quantitative and qualitative, in order to arrive at evidence-based conclusions
- LO8. Work effectively and cooperatively as a member of a learning team
Unit availability
This section lists the session, attendance modes and locations the unit is available in. There is a unit outline for each of the unit availabilities, which gives you information about the unit including assessment details and a schedule of weekly activities.
The outline is published 2 weeks before the first day of teaching. You can look at previous outlines for a guide to the details of a unit.
Modes of attendance (MoA)
This refers to the Mode of attendance (MoA) for the unit as it appears when you’re selecting your units in Sydney Student. Find more information about modes of attendance on our website.
